公开(公告)号：US20240360413A1

公开(公告)日：2024-10-31

申请号：US18755134

申请日：2024-06-26

申请人： Regents of the University of Minnesota

发明人： Jeffrey MILLER ,  Frank CICHOCKI ,  Yenan BRYCESON ,  Heinrich SCHLUMS

IPC分类号： C12N5/0783 ,  A61K35/17 ,  A61K39/00 ,  A61K39/245 ,  A61K45/06 ,  A61P35/00 ,  C12N7/00

CPC分类号： C12N5/0646 ,  A61K35/17 ,  A61K39/245 ,  A61K45/06 ,  A61P35/00 ,  C12N7/00 ,  A61K2039/572 ,  A61K2039/585 ,  C12N2501/04 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/42 ,  C12N2501/599 ,  C12N2502/1121 ,  C12N2502/1157 ,  C12N2502/1352 ,  C12N2710/16134

摘要： This disclosure describes an adaptive NK cell, an isolated population of adaptive Natural Killer (NK) cells, a composition including an adaptive NK cell, and methods for producing, preparing, and using an adaptive NK cell or an isolated population or composition including an adaptive NK cell. The adaptive NK cells may be used to treat a viral infection or a tumor.

公开(公告)号：US20240353411A1

公开(公告)日：2024-10-24

申请号：US18687744

申请日：2023-02-20

申请人： Ajou University Industry-Academic Cooperation Foundation

发明人： Hyo Eon JIN ,  Dongguk SHIN

IPC分类号： G01N33/574 ,  C07K7/06 ,  C12N7/00 ,  C12Q1/6886 ,  G01N21/78 ,  G01N33/544 ,  G01N33/553

CPC分类号： G01N33/57449 ,  C07K7/06 ,  C12N7/00 ,  C12Q1/6886 ,  G01N21/78 ,  G01N33/544 ,  G01N33/553

摘要： The present invention relates to a peptide for detecting HE4 and use thereof and, more specifically, to a peptide for detecting HE4 that specifically binds to HE4 and use thereof for diagnosing ovarian cancer. The peptide that specifically binds to HE4, according to the present invention, can detect HE4 with high sensitivity and accuracy. In addition, when the peptide is expressed in the outer coat of a bacteriophage and constructed into a bacteriophage nano self-assembly, the peptide can conveniently detect HE4 from a sample through observation of a color change with a simple imaging device such as a smartphone, and in particular, the peptide can detect HE4 included in a small amount in saliva, and thus has the advantage of being very effectively used in early diagnosis of ovarian cancer.

公开(公告)号：US20240350622A1

公开(公告)日：2024-10-24

申请号：US18682740

申请日：2022-08-11

申请人： Macfarlane Burnet Institute for Medical Research and Public Health Limited

发明人： Pantelis Poumbourios ,  Heidi Drummer

IPC分类号： A61K39/215 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/575 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20051

摘要： The field of the specification relates broadly to SARS-CoV-2 vaccine spike protein antigens and methods of using and manufacturing these antigens. The invention also relates to vectors and polynucleotides encoding the SARS-CoV-2 vaccine antigens and vaccines, kits, devices and strips comprising the coronavirus vaccine antigen. The spike protein from SARS-CoV-2 has prolines substituted at positions 986, 987 (2P or S-2P) and additional alanine cavity filling mutations at positions A1016 and A1020.

公开(公告)号：US20240350619A1

公开(公告)日：2024-10-24

申请号：US18027132

申请日：2022-05-10

申请人： GUANGZHOU RIBOBIO CO., LTD. ,  ARGORNA PHARMACEUTICALS CO., LTD.

发明人： Bill Biliang ZHANG ,  Lin MA ,  Jian WEN ,  Hong ZHANG ,  Huiling ZHONG

IPC分类号： A61K39/215 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  C12N15/11 ,  C12N15/85

CPC分类号： A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  C12N15/11 ,  C12N15/85 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/70 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2830/50

摘要： This disclosure provides vaccines and compositions based on SARS-COV-2 S protein, and specifically relates to recombinant SARS-COV-2 spike protein (Sprotein) and mRNA and DNA coding thereof. This disclosure also relates to recombinant plasmid comprising DNA sequence encoding recombinant S protein. This disclosure further relates to composition comprising the recombinant S protein and/or mRNA mentioned above, mRNA-carrier particle such as lipid nanoparticle (LNP), and composition such as a vaccine composition.

公开(公告)号：US20240350618A1

公开(公告)日：2024-10-24

申请号：US18443332

申请日：2024-02-16

申请人： UNIVERSITY OF HYDERABAD

发明人： Satyajit Mukhopadhyay ,  Anand Kumar Kondapi ,  Ritika Das ,  Miss Hema

IPC分类号： A61K39/21 ,  A61K39/00 ,  C12N7/00 ,  C12N9/90

CPC分类号： A61K39/21 ,  C12N7/00 ,  C12N9/90 ,  C12Y599/01002 ,  A61K2039/53 ,  C12N2740/16034

摘要： The present invention relates to an anti-HIV recombinant HIV-1 derived Topoisomerase IIβ kinase. It inhibits HIV-1 replication by blocking viral entry. Its recognition by envelope antibodies ID6 and 4G10 makes it a justifiable immunogen for use as vaccine candidate in form of protein, mRNA and DNA vaccine against HIV infection. Thus, the protein, mRNA and DNA of immunogenic recombinant HIV-1 derived Topoisomerase IIβ kinase and derived peptides with and without spacers can be used as a HIV vaccine.
FIG. 1, FIG. 2, FIG. 3, FIG. 4, FIG. 5, FIG. 6, FIG. 7, FIG. 7, FIG. 8, FIG. 9, FIG. 10, FIG. 11, FIG. 12, FIG. 13, FIG. 14, FIG. 15, FIG. 16.

公开(公告)号：US20240344071A1

公开(公告)日：2024-10-17

申请号：US18439380

申请日：2024-02-12

申请人： Research Institute At Nationwide Children's Hospital ,  Ludwig Institute For Cancer Research

发明人： Brian K. Kaspar ,  Kevin Foust ,  Don W. Cleveland

IPC分类号： C12N15/113 ,  A61K9/00 ,  A61K31/7105 ,  C12N7/00 ,  C12N9/02 ,  C12N15/86

CPC分类号： C12N15/1137 ,  A61K9/0019 ,  A61K31/7105 ,  C12N7/00 ,  C12N9/0089 ,  C12N15/86 ,  C12Y115/01001 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/32 ,  C12N2750/14043 ,  C12N2750/14143

摘要： The present invention relates to RNA-based methods for inhibiting the expression of the superoxide diamutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.

公开(公告)号：US20240342265A1

公开(公告)日：2024-10-17

申请号：US18626704

申请日：2024-04-04

申请人： SICHUAN ANCOCARE BIOPHARMACEUTICAL, Ltd.

发明人： Li YU

IPC分类号： A61K39/12 ,  A61K35/768 ,  A61K39/00 ,  A61P37/04 ,  C07K14/705 ,  C12N7/00

CPC分类号： A61K39/12 ,  A61K35/768 ,  A61P37/04 ,  C07K14/70532 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/585 ,  C12N2770/24122 ,  C12N2770/24132 ,  C12N2770/24134 ,  C12N2770/24162 ,  C12N2770/24171

摘要： The invention provides a recombinant West Nile virus, in which the amino acid sequence of envelope E protein is genetically modified to attenuation, and its RNA genome is inserted with a foreign gene fragment. The engineered E gene contains the mutation of five amino acids for reducing its neural virulence to the central nervous system; the integrated foreign gene between E and S1 gene makes a new chimerical virus. Thus, the present invention provides the application of this attenuated West Nile virus as a vaccine in preventive medicine and the application of the RNA-viral vector as a novel gene-drug in the pharmaceutical industry. The newly attenuated virus may fill the gap of no live-attenuated vaccine to the West Nile virus epidemic. The attenuated and recombinant virus can be used as an RNA oncolytic virus to target solid tumors, especially neural tumors, for cancer therapy with higher safety.

公开(公告)号：US20240342231A1

公开(公告)日：2024-10-17

申请号：US18426803

申请日：2024-01-30

申请人： Salk Institute for Biological Studies

发明人： Clodagh O'Shea ,  Shigeki Miyake-Stoner ,  Colin Powers

IPC分类号： A61K35/761 ,  C12N7/00 ,  C12N15/86

CPC分类号： A61K35/761 ,  C12N7/00 ,  C12N15/86 ,  C07K2319/20 ,  C12N2710/10034 ,  C12N2710/10052 ,  C12N2710/10345

摘要： Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.

公开(公告)号：US12116602B2

公开(公告)日：2024-10-15

申请号：US17930943

申请日：2022-09-09

申请人： Mayo Foundation for Medical Education and Research

发明人： Liyi Geng ,  Ping Chen ,  William S. Brimijoin ,  Yang Gao

IPC分类号： C12N9/18 ,  C07K14/00 ,  C07K14/575 ,  C12N7/00 ,  C12N15/86 ,  A61K35/76 ,  A61K35/761 ,  A61K38/00 ,  A61K38/22 ,  A61K48/00 ,  C07H21/04 ,  C12N15/861 ,  C12N15/864

CPC分类号： C12N9/18 ,  C07K14/00 ,  C07K14/5759 ,  C12N7/00 ,  C12N15/86 ,  C12Y301/01008 ,  A61K35/76 ,  A61K35/761 ,  A61K38/00 ,  A61K38/2264 ,  A61K48/00 ,  C07H21/04 ,  C12N15/861 ,  C12N15/8645 ,  C12N2750/14141 ,  C12N2750/14143

摘要： This document provides butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin as well as nucleic acids encoding such butyrylcholinesterases. This document also provides methods and materials for treating obesity and/or aggression. For example, methods for administering a nucleic acid encoding a wild-type or mutant butyrylcholinesterase having the ability to hydrolyze acyl ghrelin to a mammal under conditions wherein the level of acyl ghrelin within the mammal is reduced, under conditions wherein the rate of body weight gain of the mammal is reduced, under conditions wherein the mammal's level of aggression is reduced, and/or under conditions wherein the mammal's rate of developing stress-induced tissue damage are provided.

公开(公告)号：US20240335489A1

公开(公告)日：2024-10-10

申请号：US18751599

申请日：2024-06-24

申请人： Baylor College of Medicine ,  United States Government as Represented by the Department of Veterans Affairs

发明人： Anthony Maresso ,  Robert Ramig ,  Sabrina Green ,  Austen Terwilliger ,  Keiko Salazar ,  Justin R. Clark ,  Barbara Trautner

IPC分类号： A61K35/76 ,  A61P31/04 ,  C12N7/00

CPC分类号： A61K35/76 ,  A61P31/04 ,  C12N7/00 ,  C12N2795/10132 ,  C12N2795/10171 ,  C12N2795/10232 ,  C12N2795/10271

摘要： Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.